Literature DB >> 9713589

p53 alterations in oesophageal cancer: association with clinicopathological features, risk factors, and survival.

A G Casson1, M Tammemagi, S Eskandarian, M Redston, J McLaughlin, H Ozcelik.   

Abstract

AIM: To characterise the spectrum of p53 alterations (gene mutations and protein accumulation) in a consecutive series of surgically resected oesophageal cancers, and to evaluate associations with clinicopathological findings (age, sex, tumour histology, grade, and stage), potential risk factors (alcohol, tobacco, hot beverage consumption, history of gastrooesophageal reflux disease and antacid use), and survival.
METHODS: The case series comprised 61 sequentially accrued patients with primary oesophageal carcinomas. Genomic DNA was extracted from banked (frozen) tumours and matched normal mucosal tissue; p53 mutations (exons 4-10) were studied by means of polymerase chain reaction (PCR)/single strand conformation polymorphism (SSCP) analysis and DNA sequencing. Immunohistochemistry (DO7, CM1) was used to assess cell nuclear p53 protein accumulation. Risk factor data, overall and disease free survival were measured prospectively, and analysis was carried out at the univariate level using Kaplan-Meier survival curves with log rank tests, and in multivariate analysis using Cox's proportional hazards models (parsimonious and fully adjusted).
RESULTS: p53 mutations were found in 59% (36 of 61) and p53 protein accumulation was detected in 39% (24 of 61) of oesophageal cancers. Eighty eight per cent (23 of 26) of poorly differentiated tumours had p53 alterations compared with 57% (20 of 35) of moderate/well differentiated tumours (odds ratio (OR) = 5.575; p = 0.013). p53 mutations increased significantly with increasing consumption of hot beverages (measured by the average temperature of beverage, number consumed daily, and an index made by multiplying the two variables together) using both univariate (OR = 18.6; p = 0.0025) and multivariate (OR = 24.5; p = 0.0025) analysis. p53 alterations were associated with reduced disease free and overall survival (p = 0.051, log rank), with a univariate (unadjusted) hazard ratio (HR) of 2.241 (95% confidence limits (CL) = 0.973, 5.159; p = 0.058) for overall survival. By multivariate analysis adjusted for other relevant variables, the HR for tumours with p53 alterations was estimated at 2.913 (95% CL = 1.069, 7.936; p = 0.036) for overall survival.
CONCLUSIONS: This study reports novel p53 mutations (exon 10), and an association between increasing consumption of hot beverages as a risk factor for p53 mediated oesophageal cancer. p53 is a potentially useful prognostic marker in this disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9713589      PMCID: PMC395613          DOI: 10.1136/mp.51.2.71

Source DB:  PubMed          Journal:  Mol Pathol        ISSN: 1366-8714


  47 in total

1.  Expression of p53 in human esophageal carcinoma: an immunohistochemical study with correlation to proliferating cell nuclear antigen expression.

Authors:  H Sasano; S Miyazaki; Y Gooukon; T Nishihira; T Sawai; H Nagura
Journal:  Hum Pathol       Date:  1992-11       Impact factor: 3.466

2.  Oncogenes and onco-suppressor gene in adenocarcinoma of the oesophagus.

Authors:  J Jankowski; G Coghill; D Hopwood; K G Wormsley
Journal:  Gut       Date:  1992-08       Impact factor: 23.059

3.  Breast cancer prognostic factors: evaluation guidelines.

Authors:  W L McGuire
Journal:  J Natl Cancer Inst       Date:  1991-02-06       Impact factor: 13.506

4.  Reduction to homozygosity involving p53 in esophageal cancers demonstrated by the polymerase chain reaction.

Authors:  S J Meltzer; J Yin; Y Huang; T K McDaniel; C Newkirk; O Iseri; B Vogelstein; J H Resau
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-01       Impact factor: 11.205

5.  Hot maté drinking and precancerous lesions of the oesophagus: an endoscopic survey in southern Brazil.

Authors:  N Muñoz; C G Victora; M Crespi; C Saul; N M Braga; P Correa
Journal:  Int J Cancer       Date:  1987-06-15       Impact factor: 7.396

6.  Archival analysis of p53 genetic and protein alterations in Chinese esophageal cancer.

Authors:  W P Bennett; M C Hollstein; A He; S M Zhu; J H Resau; B F Trump; R A Metcalf; J A Welsh; C Midgley; D P Lane
Journal:  Oncogene       Date:  1991-10       Impact factor: 9.867

7.  p53 mutation and protein accumulation during multistage human esophageal carcinogenesis.

Authors:  W P Bennett; M C Hollstein; R A Metcalf; J A Welsh; A He; S M Zhu; I Kusters; J H Resau; B F Trump; D P Lane
Journal:  Cancer Res       Date:  1992-11-01       Impact factor: 12.701

8.  p53 gene mutations in Barrett's epithelium and esophageal cancer.

Authors:  A G Casson; T Mukhopadhyay; K R Cleary; J Y Ro; B Levin; J A Roth
Journal:  Cancer Res       Date:  1991-08-15       Impact factor: 12.701

9.  Expression of p53 protein in oesophageal carcinoma: clinicopathological correlation and prognostic significance.

Authors:  R Vijeyasingam; S J Darnton; K Jenner; C A Allen; C Billingham; H R Matthews
Journal:  Br J Surg       Date:  1994-11       Impact factor: 6.939

10.  Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer.

Authors:  D C Allred; G M Clark; R Elledge; S A Fuqua; R W Brown; G C Chamness; C K Osborne; W L McGuire
Journal:  J Natl Cancer Inst       Date:  1993-02-03       Impact factor: 13.506

View more
  17 in total

1.  Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence.

Authors:  R V Lord; D Salonga; K D Danenberg; J H Peters; T R DeMeester; J M Park; J Johansson; K A Skinner; P Chandrasoma; S R DeMeester; C G Bremner; P I Tsai; P V Danenberg
Journal:  J Gastrointest Surg       Date:  2000 Mar-Apr       Impact factor: 3.452

2.  Molecular biology of Barrett's esophagus and esophageal cancer:role of p53.

Authors:  Alan G Casson
Journal:  World J Gastroenterol       Date:  1998-08       Impact factor: 5.742

Review 3.  Barrett's esophagus.

Authors:  Jeffrey H Peters; Jeffrey A Hagen; Steven R DeMeester
Journal:  J Gastrointest Surg       Date:  2004-01       Impact factor: 3.452

4.  p53 immunohistochemical expression and patient prognosis in esophageal squamous cell carcinoma.

Authors:  Asuka Murata; Yoshifumi Baba; Masayuki Watanabe; Hironobu Shigaki; Keisuke Miyake; Ryuichi Karashima; Yu Imamura; Satoshi Ida; Takatsugu Ishimoto; Shiro Iwagami; Yasuo Sakamoto; Yuji Miyamoto; Naoya Yoshida; Hideo Baba
Journal:  Med Oncol       Date:  2013-09-13       Impact factor: 3.064

5.  Genomic Characterization of Esophageal Squamous Cell Carcinoma Reveals Critical Genes Underlying Tumorigenesis and Poor Prognosis.

Authors:  Hai-De Qin; Xiao-Yu Liao; Yuan-Bin Chen; Shao-Yi Huang; Wen-Qiong Xue; Fang-Fang Li; Xiao-Song Ge; De-Qing Liu; Qiuyin Cai; Jirong Long; Xi-Zhao Li; Ye-Zhu Hu; Shao-Dan Zhang; Lan-Jun Zhang; Benjamin Lehrman; Alan F Scott; Dongxin Lin; Yi-Xin Zeng; Yin Yao Shugart; Wei-Hua Jia
Journal:  Am J Hum Genet       Date:  2016-04-07       Impact factor: 11.025

6.  Targeted next-generation sequencing supports epidermoid metaplasia of the esophagus as a precursor to esophageal squamous neoplasia.

Authors:  Aatur D Singhi; Christina A Arnold; Dora M Lam-Himlin; Marina N Nikiforova; Lysandra Voltaggio; Marcia I Canto; Kevin M McGrath; Elizabeth A Montgomery
Journal:  Mod Pathol       Date:  2017-07-21       Impact factor: 7.842

7.  p53 is an independent prognostic factor in operable esophageal squamous cell carcinoma: a large-scale study with a long follow-up.

Authors:  Xiao-Ling Xu; Wei-Hui Zheng; Kai-Yi Tao; Xian-Xing Li; Wei-Zhen Xu; Yin Wang; Shuang-Mei Zhu; Wei-Min Mao
Journal:  Med Oncol       Date:  2014-10-01       Impact factor: 3.064

8.  Clinical significance of p53 mutations in adenocarcinoma of the esophagus and cardia.

Authors:  A P Ireland; D K Shibata; P Chandrasoma; R V Lord; J H Peters; T R DeMeester
Journal:  Ann Surg       Date:  2000-02       Impact factor: 12.969

9.  A functional epidermal growth factor (EGF) polymorphism, EGF serum levels, and esophageal adenocarcinoma risk and outcome.

Authors:  Michael Lanuti; Geoffrey Liu; Jonathan M Goodwin; Rihong Zhai; Bryan C Fuchs; Kofi Asomaning; Li Su; Norman S Nishioka; Kenneth K Tanabe; David C Christiani
Journal:  Clin Cancer Res       Date:  2008-05-15       Impact factor: 12.531

10.  Alternative splicing of the FGF antisense gene: differential subcellular localization in human tissues and esophageal adenocarcinoma.

Authors:  Shuo Cheng Zhang; Christie Barclay; Leigh Ann Alexander; Laurette Geldenhuys; Geoffrey A Porter; Alan G Casson; Paul R Murphy
Journal:  J Mol Med (Berl)       Date:  2007-06-14       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.